I agree with both yourself and IndexInvesfor.
I feel knowing Zantrene's pharmacological effect (works as an FTO inhibitor) versus knowing its MoA are completely separate.
As you know there are many drugs that function with unknown/unclear drug interactions with receptors and uncertainty of how it produces its therapeutic effect.
Commonly, paracetamols are understood to work to treat pain and reduce fevers. Yet, its MoA is still unknown (specific molecular targets).
Knowing both Zantrene's effect and its MoA would unquestionably be amazing to know. However, they're not intricably linked to FDA approval.
For anyone interested this is a list of drugs with unknown MoA:
Acamprosate
Antidepressants
Armodafinil
Cannabidiol
Cyclobenzaprine
Demeclocycline
Fabomotizole
Lithium
Meprobamate
Methocarbamol
Paracetamol
Phenytoin
PRL-8-53
Metformin
Thalidomide
I agree with both yourself and IndexInvesfor.I feel knowing...
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.89 |
Change
0.120(6.80%) |
Mkt cap ! $321.0M | |||
| Open | High | Low | Value | Volume |
| $1.78 | $1.93 | $1.78 | $563.4K | 302.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 108 | $1.88 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.90 | 4926 | 1 |
View Market Depth
| Last trade - 16.10pm 11/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |